Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 8/20 | 0.55 |
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 4/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15618202 | 0.86 | MKNK1 (0.50) | MKNK1BRAFTNNI3KPOLBMAPT | |
| SCHEMBL15618333 | 0.84 | MKNK1 (0.66) | MKNK1BRAFTNNI3KSYK | |
| SCHEMBL18167313 | 0.84 | MKNK1 (0.53) | MKNK1BRAFTNNI3KKIF11SYK | |
| SCHEMBL15618296 | 0.83 | MKNK1 (0.58) | MKNK1BRAFTNNI3KKIF11SYK | |
| SCHEMBL15618647 | 0.83 | MKNK1 (0.58) | MKNK1KIF11SYKPOLBEGFR | |
| SCHEMBL15618299 | 0.83 | MKNK1 (0.58) | MKNK1KIF11SYKPOLBEGFR | |
| SCHEMBL15618209 | 0.82 | MKNK1 (0.55) | MKNK1SYKEGFRKDR | |
| SCHEMBL15631582 | 0.80 | MKNK1 (0.51) | MKNK1BRAFTNNI3KKIF11SYK | |
| SCHEMBL15618199 | 0.80 | MKNK1 (0.61) | MKNK1BRAFTNNI3KPOLBMAPT | |
| SCHEMBL15618488 | 0.80 | MKNK1 (0.53) | MKNK1KIF11SYKPOLBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2897957-B1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | Bayer Pharma AG (DE) | 2016-10-26 | — | — | EP | claimed |
| CN-104797582-B | Substituted pyrrolo-pyrimidine radicals amino-benzothiazole ketone as MKNK inhibitors of kinases | 拜耳药业股份公司 | 2016-10-12 | — | — | CN | claimed |
| EP-2897957-B1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | Bayer Pharma AG (DE) | 2016-10-26 | — | — | EP | disclosed |
| CN-104797582-B | Substituted pyrrolo-pyrimidine radicals amino-benzothiazole ketone as MKNK inhibitors of kinases | 拜耳药业股份公司 | 2016-10-12 | — | — | CN | disclosed |
| US-9382255-B2 | Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-05 | — | — | US | disclosed |
| US-9382255-B2 | Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-05 | — | — | US | disclosed |
| US-20150239891-A1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-27 | — | — | US | disclosed |
| US-20150239891-A1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-27 | — | — | US | disclosed |
| EP-2897957-A1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2015-07-29 | — | — | EP | disclosed |
| CN-104797582-A | Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors | Bayer Pharma AG | 2015-07-22 | — | — | CN | disclosed |
| WO-2014044691-A1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-03-27 | — | — | WO | disclosed |
| US-20100113606-A1 | AMINOPROPANOL MODULATORS OF BETA-1 ADRENERGIC RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113606-A1 | AMINOPROPANOL MODULATORS OF BETA-1 ADRENERGIC RECEPTOR | ADRB1, ADRB2, ADRB3 | MKNK1 3686/4885BRAF 3808/4885TNNI3K 3949/4885 |
| US-20150239891-A1 | SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS | MKNK1, MKNK2, MAP3K20 | MKNK1 1/4885BRAF 246/4885TNNI3K 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.